Michael P. Ludwig

Michael P. Ludwig

Auto-generated profile, based on publicly available information

Michael P. Ludwig

Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Science Advances
Verified
Journal Article
Open access
MGMatthew D. Galbraith
Matthew D. Galbraith
ARAngela L. Rachubinski
Angela L. Rachubinski
KSKeith P. Smith
Keith P. Smith
PAPaula Araya
Paula Araya
KWKatherine A. Waugh
Katherine A. Waugh
JEJoaquin M. Espinosa
Joaquin M. Espinosa
Individuals with Down syndrome (DS) display chronic hyperactivation of interferon signaling. However, the clinical impacts of interferon hyperactivity in DS are ill-defined. Here, we describe a multiomics investigation of interferon signaling in hundreds of individuals with DS. Using interferon scores derived from the whole blood transcriptome, we defined the proteomic, immune, metabolic, and clinical features associated with interferon hyperactivity in DS. Interferon hyperactivity associates with a distinct proinflammatory phenotype and dysregulation of major growth signaling and morphogenic pathways. Individuals with the highest interferon activity display the strongest remodeling of the peripheral immune system, including increased cytotoxic T cells, B cell depletion, and monocyte activation. Interferon hyperactivity accompanies key metabolic changes, most prominently dysregulated tryptophan catabolism. High interferon signaling stratifies a subpopulation with elevated rates of congenital heart disease and autoimmunity. Last, a longitudinal case study demonstrated that JAK inhibition normalizes interferon signatures with therapeutic benefit in DS. Together, these results justify the testing of immune-modulatory therapies in DS.

19 May 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
MLMichael P. Ludwig
Michael P. Ludwig
MGMatthew D. Galbraith
Matthew D. Galbraith
NENeetha Paul. Eduthan
Neetha Paul. Eduthan
AHAmanda A. Hill
Amanda A. Hill
MCMichael R. Clay
Michael R. Clay
KSKelly D. Sullivan
Kelly D. Sullivan
Liposarcoma is the most commonly occurring soft-tissue sarcoma and is frequently characterized by amplification of chromosome region 12q13–15 harboring the oncogenes MDM2 and CDK4. This unique genetic profile makes liposarcoma an attractive candidate for targeted therapeutics. While CDK4/6 inhibitors are currently employed for treatment of several cancers, MDM2 inhibitors have yet to attain clinical approval. Here, we report the molecular characterization of the response of liposarcoma to the MDM2 inhibitor nutlin-3. Treatment with nutlin-3 led to upregulation of two nodes of the proteostasis network: the ribosome and the proteasome. CRISPR/Cas9 was used to perform a genome-wide loss of function screen that identified PSMD9, which encodes a proteasome subunit, as a regulator of response to nutlin-3. Accordingly, pharmacologic studies with a panel of proteasome inhibitors revealed strong combinatorial induction of apoptosis with nutlin-3. Mechanistic studies identified activation of the ATF4/CHOP stress response axis as a potential node of interaction between nutlin-3 and the proteasome inhibitor carfilzomib. CRISPR/Cas9 gene editing experiments confirmed that ATF4, CHOP, and the BH3-only protein, NOXA, are all required for nutlin-3 and carfilzomib-induced apoptosis. Furthermore, activation of the unfolded protein response using tunicamycin and thapsigargin was sufficient to activate the ATF4/CHOP stress response axis and sensitize to nutlin-3. Finally, cell line and patient-derived xenograft models demonstrated combinatorial effects of treatment with idasanutlin and carfilzomib on liposarcoma growth in vivo. Together, these data indicate that targeting of the proteasome could improve the efficacy of MDM2 inhibitors in liposarcoma. Significance: Targeting the proteasome in combination with MDM2 inhibition activates the ATF4/CHOP stress response axis to induce apoptosis in liposarcoma, providing a potential therapeutic approach for the most common soft-tissue sarcoma.

24 November 2025
Verified
Other
Open access
MLMichael P. Ludwig
Michael P. Ludwig
MGMatthew D. Galbraith
Matthew D. Galbraith
NENeetha Paul Eduthan
Neetha Paul Eduthan
AHAmanda A. Hill
Amanda A. Hill
MCMichael R. Clay
Michael R. Clay
KSKelly D. Sullivan
Kelly D. Sullivan
Nutlin-3-proteasome inhibitor drug interaction SRB data.

24 November 2025
Verified
Other
Open access
MLMichael P. Ludwig
Michael P. Ludwig
MGMatthew D. Galbraith
Matthew D. Galbraith
NENeetha Paul Eduthan
Neetha Paul Eduthan
AHAmanda A. Hill
Amanda A. Hill
MCMichael R. Clay
Michael R. Clay
KSKelly D. Sullivan
Kelly D. Sullivan
GSEA of nutlin-3-treated LPS transcriptome data.

1 August 2023
Verified
Other
Open access
MLMichael P. Ludwig
Michael P. Ludwig
MGMatthew D. Galbraith
Matthew D. Galbraith
NENeetha Paul Eduthan
Neetha Paul Eduthan
AHAmanda A. Hill
Amanda A. Hill
MCMichael R. Clay
Michael R. Clay
KSKelly D. Sullivan
Kelly D. Sullivan
Nutlin-3-treated LPS transcriptome analyses.

1 August 2023
Verified
Other
Open access
MLMichael P. Ludwig
Michael P. Ludwig
MGMatthew D. Galbraith
Matthew D. Galbraith
NENeetha Paul Eduthan
Neetha Paul Eduthan
AHAmanda A. Hill
Amanda A. Hill
MCMichael R. Clay
Michael R. Clay
KSKelly D. Sullivan
Kelly D. Sullivan
Supplementary File 1 from Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway